anti-ILT3 antibodies

N/A

Report date: 2025/03/14 16:49:05

Base Information

Drug Nameanti-ILT3 antibodies
Drug Alias Nameanti-ILT3 mAb (Merck)LILRB4 targeting antibody (Merck)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionLeukocyte immunoglobulin-like receptor subfamily B member 4 inhibitors
TargetsLeukocyte immunoglobulin-like receptor subfamily B member 4
Therapy Area/IndicationsPancreatic NeoplasmsMelanomaLeukemia, Myeloid, Acute +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesMerck & Co Inc
Inactive CompaniesN/A
Active IndicationsPancreatic NeoplasmsMelanomaLeukemia, Myeloid, Acute
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A